| Literature DB >> 24393469 |
Toam Katz, Andreas Frings1, Stephan J Linke, Gisbert Richard, Vasyl Druchkiv, Johannes Steinberg.
Abstract
BACKGROUND: This study examined the refractive and visual outcome of wavefront-optimized laser in situ keratomileusis (LASIK) in eyes with low myopia and compound myopic astigmatism ≤ 0.75 diopter (D).Entities:
Mesh:
Year: 2014 PMID: 24393469 PMCID: PMC3890523 DOI: 10.1186/1471-2415-14-1
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Epidemiological data and refractive parameters. Displayed as aggregate data for each of the cylinder groups
| | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37 | 24,2 | 81 | 52,9 | 35 | 22,9 | 153 | 100 | |||||||||
| 17 | 45,95 | 39 | 48,15 | 18 | 51,43 | 74 | 48,37 | |||||||||
| 20 | 54,05 | 42 | 51,85 | 17 | 48,57 | 79 | 51,63 | |||||||||
| 37 | 100 | 81 | 100 | 35 | 100 | 153 | 100 | |||||||||
| | ||||||||||||||||
| 23/60 | 38.84(10.56) | 20/61 | 39.68(10.65) | 24/63 | 43.49(9.28) | 20/63 | 40.35(10.42) | |||||||||
| 70/168 | 121.47(23.13) | 62/169 | 121.75(28.8) | 63/166 | 114.32(29.13) | 62/169 | 120.01(27.63) | |||||||||
| | ||||||||||||||||
| -2.88/-0.63 | -2(0.7) | -1/1 | 0.01 (0.42) | -3/-0.5 | -2.27 (0.68) | -1.5/1 | -0.06 (0.59) | -2.88/-0.63 | -1.96 (0.74) | -1.25/1.13 | -0.16 (0.61) | -3/-0.5 | -2.13 (0.71) | -1.5/1.13 | -0.06 (0.56) | |
| -2.75/-0.5 | -1.88 (0.7) | -0.75/1.25 | 0.29 (0.42) | -2.75/-0.25 | -2.02 (0.68) | -1.25/1.5 | 0.27 (0.66) | -2.5/-0.25 | -1.59 (0.74) | -1/1.75 | 0.16 (0.63) | -2.75/-0.25 | -1.88 (0.72) | -1.25/1.75 | 0.25 (0.6) | |
| -0.25/-0.25 | -0.25 (0) | -1.25/0 | -0.55 (0.29) | -0.5/-0.5 | -0.5(0) | -1.75/0 | -0.66 (0.4) | -0.75/-0.75 | -0.75 (0) | -1.5/0 | -0.65 (0.41) | -0.75/-0.25 | -0.5(0.17) | -1.75/0 | -0.63 (0.38) | |
| 0.1/2 | 0.78 (0.3) | -0.11 | 0.05 (0.1) | 0.1/2 | 0.84 (0.3) | -0.18 | 0.08 (0.1) | 0.1/2 | 0.75 (0.4) | -0.18 | 0.07 (0.1) | 0.1/2 | 0.81 (0.3) | -0.18 | 0.07 (0.1) | |
†The difference in age was not significant, F(2,152) = 2.178, p = 0.117.
‡ The difference in follow up time was not significant, K-W (2) = 1.9, p = 0.387.
Efficacy (EI) and safety (SI), displayed by preoperative astigmatic cylinder magnitude
| 37 | 81 | 35 | 153 | ||
| 0.93(0.68-1) | 0.75(0.67-0.94) | 0.8(0.67-1) | 0,211 | 0.78(0.67-0.92) | |
| 1(1–1.08) | 1(0.92-1.09) | 1.05(0.9-1.2) | 0,659 | 1(0.94-1.11) | |
| 9 | 15 | 6 | 30 | ||
| 0.82(0.65-0.94) | 0.89(0.78-1) | 0.83(0.73-0.98) | 0.81(0.67-0.93) | ||
| 0.91(0.83-1.03) | 1.04(1–1.1) | 1.04(0.99-1.22) | 1(0.9-1.07) | ||
| 28 | 66 | 29 | 123 | ||
| 0.93(0.73-1) | 0.75(0.67-0.94) | 0.8(0.65-1) | 0.76(0.66-1) | ||
| 1(1–1.08) | 1(0.92-1.09) | 1.05(0.9-1.2) | 1(0.92-1.1) |
* Median(Q25-Q75) Q25 = 25th quartile; Q75 = 75th quartile.
**Tested with Kruskal-Wallis Test.
Figure 1Attempted versus achieved spherical equivalent (SE) correction at 4 months, displayed by preoperative astigmatic cylinder magnitude: A) 0.25 D, B) 0.50 D, and C) 0.75 D.
Predictability of spherical equivalent displayed by preoperative astigmatic cylinder magnitude
| | | |||||
|---|---|---|---|---|---|---|
| | | |||||
| 0 | 1 | 31 | 5 | 0 | 37 | |
| | | |||||
| 4 | 12 | 52 | 13 | 0 | 81 | |
| | | |||||
| 1 | 10 | 19 | 4 | 1 | 35 | |
*Exact significance, Fisher’s Exact Test = 0.027.
Figure 2Change in lines of A) efficacy, and B) safety (preoperatively vs. 4 months postoperatively).
Figure 3Preoperative CDVA versus UDVA 4 months postoperatively.
Cylinder axis preop. vs. postop, number of cases with axis change after treatment
| | |||
|---|---|---|---|
| 12 (24%) | 26 (52%) | 12 (24%) | |
| 17 (29%) | 30 (52%) | 11 (19%) | |
| 8 (18%) | 25 (56%) | 12 (27%) | |
| | |||
| 20 (24%) | 44 (51%) | 22 (26%) | |
| 13 (24%) | 30 (55%) | 12 (22%) | |
| 4 (33.3%) | 7 (58.3%) | 1 (8.3%) | |
| | |||
| | |||
| WTR (n = 86) | Oblique (n = 55) | ATR (n = 12) | |
| 27 (54%) | 18 (36%) | 5 (10%) | |
| 33 (57%) | 21 (36%) | 4 (7%) | |
| 26 (57.8%) | 16 (35.6%) | 3 (6.7%) | |
§ Not significant, χ2(4) = 2.18, p = 0.704.
Not significant, Fisher’s Exact Test, p = 0.756.
‡ Not significant, Fisher’s Exact Test, p = 0.976.
Vectors and indices examined by the Alpins method: Data
| 0.25 /0.25 | 0.25(0.25/0.25) | 0.50 / 0.50 | 0.50(0.50/0.50) | 0.75 / 0.75 | 0.75(0.75/0.75) | 0.25 / 0.75 | 0.50(0.38/0.50) | ||
| 3 / 180 | 87(53/142.5) | 3 / 180 | 80(50/132.75) | 3 / 177 | 94(29/121.5) | 3 / 180 | 86(50/131.5) | ||
| 0.05 /3.20 | 0.64(0.33/0.83) | 0.02 / 2.14 | 0.91(0.61/1.24) | 0.21 / 1.92 | 0.99(0.61/1.25) | 0.02 / 3.20 | 0.82(0.54/1.23) | ||
| 19 / 172 | 82(62.2/109.09) | 4 / 177 | 82(57.66/113.36) | 5 / 173 | 96(68.44/122.09) | 4 / 177 | 86(61.3/113.84) | ||
| 0.00 /3.00 | 0.50(0.31/0.94) | 0.00 / 1.75 | 0.50(0.25/1.00) | 0.00 / 1.50 | 0.50(0.50/1.00) | 0.00 / 3.00 | 0.50(0.50/1.00) | ||
| 0 / 180 | 138.5(21.25/166.75) | 0 / 180 | 122.5(21.25/164) | 0 / 180 | 63(22.5/163.5) | 0 / 180 | 125(21.5/164.5) | ||
| Correction index | 0.21 /12.78 | 2.57(1.3/3.31) | 0.03 / 4.28 | 1.82(1.23/2.49) | 0.28 / 2.56 | 1.32(0.82/1.67) | 0.03 /12.78 | 1.77(1.11/2.51) | |
| Magnitude of error | -0.2 / 2.95 | 0.39(0.08/0.58) | -0.48 / 1.64 | 0.41(0.11/0.74) | -0.54 / 1.17 | 0.24(-0.14/0.5) | -0.54 / 2.95 | 0.37(0.04/0.66) | |
| Angle of error | -119.26 /146 | -2.08(-44.7/30.49) | -175.8 /142.45 | 0.5(-11.47/13.82) | -69.32 /159.39 | 0(-11.92/12.96) | -175.8 /159.39 | 0(-15.53/14.66) | |
| Index of success | 0 / 12 | 2(1.25/3.75) | 0 / 3.5 | 1(0.5/2) | 0 / 2 | 0.67(0.67/1.33) | 0 / 12 | 1(0.67/2) | |
| Flattening Index | 0.02 /12.57 | 1.41(0.7/2.72) | 0.03 / 4.24 | 1.11(0.52/1.78) | 0.02 / 2.49 | 0.87(0.48/1.15) | 0.02 /12.57 | 1(0.55/1.82) | |
* Tested with non-parametric Kruskal-Wallis Test.
Efficacy (EI) and safety (SI) predictability
| N total (Eyes/Patients) | 50 | 58 | 45 | |
| EI Total* | 0.80(0.67-1.0) | 0.75(0.67-1.0) | 0.82(0.70-1.0) | 0,414 |
| SI Total* | 1(0.92-1.10) | 1(0.92-1.10) | 1.0(0.93-1.10) | 0,985 |
* Median(Q25-Q75) Q25 = 25th quartile; Q75 = 75th quartile.
**Tested with Kruskal-Wallis Test.
Predictability, displayed by preoperative cylinder axis
| | | |||||
|---|---|---|---|---|---|---|
| | | |||||
| 1 | 9 | 34 | 6 | 0 | 50 | |
| | | |||||
| 3 | 8 | 38 | 9 | 0 | 58 | |
| | | |||||
| 1 | 6 | 30 | 7 | 1 | 45 | |
*Exact significance, Fisher’s Exact Test = 0.940.
Efficacy (EI), and safety (SI) predictability
| N total (Eyes/Patients) | 51 | 102 | |
| EI total* | 0.82(0.67-1.0) | 0.78(0.67-1.0) | 0,823 |
| SI total* | 1.0(0.91-1.13) | 1.0(0.98-1.09) | 0,762 |
Predictability, displayed by axis change after treatment
| | | |||||
|---|---|---|---|---|---|---|
| | | |||||
| 2 | 6 | 38 | 5 | 0 | 51 | |
| | | |||||
| 3 | 17 | 64 | 17 | 1 | 102 | |
*Exact significance, Fisher’s Exact Test = 0.589.